Abstract
Aim:HER2is a proto-oncogene expressed in 10-30% of gastric adenocarcinomasand is an ideal target for inhibition in malignancy withhigh recurrence and dismal survival rates. Materials & methods: A systematic search was conducted via PubMed, Google Scholarand theclinicaltrials.gov database to report the results of ongoing and past studies investigating HER2 inhibitors in gastric cancer. Results: Twenty-five studies were included; ToGA trial is the pivotal trial approving the use of trastuzumab in metastatic gastric cancer, followed by more studies investigating other HER2 inhibitors in this setting, as well as in local and locoregional malignancy. Conclusion: Anti-HER2 molecules are proving efficacy and safety in gastric cancer; the evidence is growingand association with other cancer agents is under investigation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
